Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC? - authors' reply.
The Chinese University of Hong Kong, Sir YK Pau Cancer Center, State Key Laboratory of Southern China, Prince of Wales Hospital, Hong Kong, China. Electronic address: tony@clo.cuhk.edu.hk.
Tony S K
TSK
Mok
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong, China.
Yi-Long
YL
Wu
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male